Larimar Therapeutics Inc - Rasio nilai perusahaan marang dodolan LRMR

Logo perusahaan publik Larimar Therapeutics, Inc. (LRMR)

Strong confidence from patient communities and investors bolsters the market position of Larimar Therapeutics (LRMR). This enterprise value-to-revenue chart illustrates the asset's dynamics, where the value 0.00 describes the current level. Larimar Therapeutics (LRMR) aims for a monopoly in Friedreich's ataxia therapy via the nomlabofusp protein while scaling its pipeline. Future revenues are based on the commercialization of innovative treatments for rare genetic pathologies.

Larimar Corp (LRMR): Rasio nilai perusahaan marang pendapatan saka 23.11.2025 nganti 20.11.2026

LRMR (Larimar Pharma): rincian analitis lan laporan miturut indikator

Pambiji fundamental perusahaan:LRMR (larimartx.com)
Produk seri Larimar Therapeutics Inc

Larimar Therapeutics (LRMR) delegates production and testing to external contractors, making its cost structure dependent on vendors. The EV/Sales metric assesses the total business value, net of debt, per unit of revenue. Investors utilize this ratio to determine if an asset is overvalued relative to its operating income. Low values often signal that the issuer is undervalued. By analyzing the historical EV/Sales trend, one can identify abnormal valuation deviations.